We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

INO's latest try at bringing a treatment to market is INO-3107, for which it expects to submit a BLA in the second half of 2024. Potential market size if the BLA is successful is $770 million ...

Neuroophthalmologic abnormalities associated with multiple sclerosis, including acute demyelinating optic neuritis and internuclear ophthalmoplegia, are described in detail. Current and emerging ...

Inovio announces the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share. The company will also offer pre-funded warrants to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

En esta ocasión podrás encontrar la versión más realista de Ino Yamanaka que nos ayuda a saber cómo será cuando finalmente se estrene el prometido live-action de este anime y manga.

DON is the most common entity to affect the afferent visual pathways in MS, while saccadic abnormalities, INO, smooth pursuit abnormalities and abnormalities of the VOR are among the more common ...

At close: May 8 at 4:00 PM EDT ...

INO-6172 is under clinical development by Inovio Pharmaceuticals and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human ...

As of April 19 at 12:16 PM EDT. Market Open.